Company intelligence / Profile preview

Mold

Ownership: Private
Development stage: Other

Overview

Mold is an early-stage biotechnology company focused on developing novel therapeutic solutions for fungal infections. The company leverages advanced molecular biology and screening techniques to identify new targets within fungal pathogens that are resistant to current standard-of-care treatments. By focusing on unique aspects of fungal physiology, Mold aims to create a new class of antifungal agents with improved efficacy and safety profiles. Their research is particularly directed toward addressing the growing global health threat of multi-drug resistant fungal strains in immunocompromised patients.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Mold.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mold.

Explore the full profile